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Objective. The purpose of this study was to investigate prognostic impact of cholesterol and its subfractions among 75-year-old
people from the general population. Methods and Results. The study comprised a random sample (222 women and 210 men) from
the general population (participation rate 70%). During 10-year follow-up, 19% of women and 35% of men experienced a major
cardiovascular event (MCVE). The all-cause mortality was 29% for women and 47% for men. After adjustment for cardiovascular
risk factors, a low level of high-density lipoprotein cholesterol (HDL-C) was signiﬁcantly associated with MCVE (P = .006) and
mortality (P = .011) in men but not in women. The prognostic sex disparity was nearly signiﬁcant (P = .051 for MCVE and
.067 for mortality). The associations of adjusted HDL-C to MCVE and mortality were unchanged after excluding individuals
with prevalent stroke or MI. Total cholesterol and low-density lipoprotein cholesterol (LDL-C) were not signiﬁcantly related to
prognosis in either sex. Main Conclusions. HDL-C was associated with dismal prognosis in men but not in women. Elderly men
with HDL-C < 40mg/dL deserve particular attention for cardiovascular prevention.
Copyright © 2009 G¨ oran Nilsson et al. This is an open access article distributed under theCreative Commons AttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
In middle-aged women and men there is a strong and
graded association between total cholesterol and low-density
lipoprotein cholesterol (LDL-C) concentrations and cardio-
vascular events as well as total mortality [1–4]. On the
contrary, in middle-aged people low levels of high-density
lipoprotein cholesterol (HDL-C) have been shown to be
an independent risk factor of atherosclerotic disease [4–7].
However, in elderly people, reports on whether survival and
atherosclerotic disease relates to the levels of cholesterol and
its fractions are conﬂicting [4, 8–11]. In particular, reports
on the relationship between survival and the serum levels of
total cholesterol, LDL-C, and HDL-C are scanty in women
above 75.
Each age class represents survivors from younger age
classes. Therefore, risk indicators may not be the same in
diﬀerent age groups. Thus, persons suﬀering adverse eﬀects
of abnormal levels of cholesterol and its subfractions may
have died before the age of 75, leaving room for new risk
factor patterns to emerge. Among the oldest people the
mortality increases rapidly, and it is therefore reasonable to
assume a rapidly changing risk factor pattern. In risk factor
analyses, all elderly people above a certain age, for instance
65 or 70, are usually evaluated as a homogenous group. Such
a practice may hide important details. Furthermore, the risk
factorpatternsofacertainageclassmaychangeoverdecades.
The risk factor patterns of 75-year old people may nowadays
be diﬀerent from that found some decades ago.
The purpose of this study was to investigate the relations
between the serum levels of total cholesterol and its sub-
fractions and long-term prognosis in a cohort of 75-year-old
men and women.
2. Methods
2.1. Study Population. The study population has previously
been described elsewhere [12]. In 1997 there were 11002 Current Gerontology and Geriatrics Research
inhabitants of the city of V¨ aster˚ as, born in 1922, making
them 75 years of age. A random sample of 618 of these
individuals was invited to participate in a cardiovascular
health survey. The city of V¨ aster˚ as, with a total population
of 130000, is situated in the central part of Sweden, and the
populationisrepresentativeofSwedenfromasocioeconomic
point of view. The invitation was accepted by 433 subjects
(223 women and 210 men) corresponding to a participation
rate of 70%. The reasons for nonparticipation were that the
individual could not be reached (n = 29), the person had
died before the examination (n = 2), language diﬃculties
or logistical problems (n = 26), locomotive impairment
(n = 28), unwillingness because of disease under treatment
(n = 54), or unknown (n = 46). The blood sample from one
woman was missing, and consequently the examined cohort
included 222 women and 210 men. The study was approved
by the research ethics committee of Uppsala University,
Sweden.
2.2. Baseline Examination. Blood samples were collected in
the morning with the subjects in a fasting state. Total serum
cholesterolandHDL-Cweredeterminedenzymaticallyusing
an automated analyzer system (Hitachi 717, Boehringer
Mannheim). Non-HDL-C was deﬁned as total cholesterol
minus HDL-C. LDL-C was calculated using the Friedewald
formula(13).ThisformuladoesnotpermitcomputingLDL-
Ca tt r i g l y c e r i d el e v e l s>400mg/dL. Consequently LDL-C
values were missing in 8 persons. The coeﬃcient of variation
for total cholesterol was 1.5% at 124mg/dL and 1.6% at
297mg/dL; for HDL-C 2.7% at 34mg/dL and 2.7% at
93mg/dL.
Blood pressure was measured with a mercury sphygmo-
manometer with the subjects in a supine position and having
relaxed for ﬁve minutes. Diagnosis of previous myocardial
infarction, stroke, and diabetes was based on self-reported
history of disease veriﬁed by medical records. Hypertension
was deﬁned as self-reported physician-diagnosed high blood
pressure in combination with regular antihypertensive treat-
ment.
2.3. Follow-Up. Major cardiovascular event (MCVE),
deﬁned as hospitalization or death caused by myocardial
infarction, stroke, or ruptured abdominal aortic aneurysm,
was selected as the primary end-point. The secondary
end-point was all-cause mortality. Follow-up information
on MCVE was based on the Swedish Hospital Discharge
register and the Cause of Death register (with available
data up until December 31, 2006). The tenth revision
of the International Statistical Classiﬁcation of Diseases
(ICD) was used to identify myocardial infarction (I21–I22),
stroke (I61–I66), and ruptured abdominal aortic aneurysm
(I71.3). Information on all-cause death was based on the
Swedish Population register (with available data up until
December 31, 2007). The registers were linked to the
individuals by the unique personal identiﬁcation number
of all citizens in Sweden. The participants were followed
from the index examination in 1997 until they reach an
end-point or December 31, 2006 (MCVE) or December 31,
2007 (all-cause mortality) at which time they were censored.
In order to achieve information from the Hospital
Discharge register, a renewed written informed consent
was required from the participants still alive during 2007.
Because of diﬃculties in reaching some participants and
refusal from others, 38 persons were lost to follow-up in this
register, leaving 394 individuals to be analyzed regarding the
MCVE. No participants were lost to follow-up concerning
all-cause mortality.
2.4. Statistics. Continuous variables were summarized by
median and interquartile range and categorical variables
by counts and proportions. The Wilcoxon Mann-Whitney
rank sum test was used to compare groups for continuous
variables. Categorical variables were compared using a two-
sided Fisher’s exact test.
The relations of cholesterol and its subfractions to out-
come were investigated by the use of Cox proportional haz-
ards regression models in sex-stratiﬁed univariable analyses.
The assumption of proportionality of hazards was assessed
by including time-dependent covariates in the models. The
relations of HDL-C to MCVE and all-cause mortality were
evaluated by multivariable Cox regression models adjusting
for potential risk factors (body mass index, smoking, non-
HDL-C, triglycerides, diabetes, hypertension, and previous
myocardialinfarction).Foradequatecontrolofconfounders,
covariates were retained in the models regardless of their
statistical signiﬁcance. To investigate the sex diﬀerence in
the strength of association between HDL-C and outcome,
we besides HDL-C included sex and the interaction between
sex and HDL-C in a multivariable Cox regression model. To
detect potential collinearity that could disturb our analyses,
forward and backward stepwise analyses were performed.
The inclusion and removal probability limits were set at 0.05
and 0.10.
Survival curves were generated by means of Kaplan-
Meier estimates, and diﬀerences in survival were compared
by the log-rank test. All tests were two tailed and a P-
value <.05 was considered statistically signiﬁcant. The SPSS
version14.0(SPSSInc.,Chicago,Ill)wasusedforallanalyses.
3. Results
Baseline characteristics of the examined cohort are shown in
Table 1. There was a notable sex disparity concerning serum
levels of HDL-C and total cholesterol as well as concerning
prevalence of previous myocardial infarction.
During a median follow-up period of 9.5 years, 38 (19%)
women and 68 (35%) men experienced an MCVE (number
o fM C V Ep e ry e a rp e r1 0 0p e r s o n sa tr i s k2 . 3f o rw o m e na n d
4.9formen,P<. 001).Speciﬁcally,theregisteredeventswere
nonfatal and fatal myocardial infarction (n = 38 and n =
17, resp.), nonfatal and fatal stroke (n = 34 and n = 10,
resp.),andnonfatalandfatalaorticrupture(n = 1andn = 6,
resp.). Concerning all-cause mortality, the median follow-up
was 10.5 years during which 65 (29%) women and 98 (47%)Current Gerontology and Geriatrics Research 3
Table 1: Baseline characteristics of the 75-year-old participants. Values are median (interquartile range) and number (%).
Men (n = 210) Women (n = 222) P-value
Total cholesterol, mg/dL† 228 (205–259) 252 (224–276) <.001
LDL-C, mg/dL∗† 147 (120–173) 159 (132–184) .001
HDL-C, mg/dL† 53 (45–60) 63 (52–75) <.001
Non-HDL-C, mg/dL† 176 (152–206) 187 (156–216) .010
Total cholesterol/HDL-C ratio 4.3 (3.7–5.2) 3.9 (3.2–5.0) .003
Triglycerides, mg/dL† 134 (98–172) 128 (98–181) .92
Body mass index, kg/m2 25.2 (23.6–26.9) 26.0 (23.4–28.9) .011
Systolic blood pressure, mmHg∗ 160 (150–180) 165 (150–190) .007
Diastolic blood pressure, mmHg∗ 85 (80–90) 85 (80–90) .84
Current smoking 34 (16) 19 (9) .116
Previous myocardial infarction 31 (15) 10 (5) <.001
Previous stroke 6 (3) 8 (4) .22
Previously known hypertension 55 (26) 63 (28) .67
Diabetes 15 (7) 17 (8) .49
Lipid lowering drugs 8 (4) 7 (3) .78
∗Data on blood pressure and LDL-C were missing in 11 and 8 cases, respectively.
†To convert total cholesterol, HDL-C, and LDL-C from mg/dL to mmol/L, divide by 39. To convert triglycerides from mg/dL, to mmol/L divide by 89.
men died (number of death per year per 100 persons at risk
3.1 for women and 5.5 for men, P<. 001).
Serum levels of HDL-C were signiﬁcantly related to both
MCVE and all-cause mortality in men but not in women
(Table 2). These associations did not substantially change
after adjustment for the potentially confounding risk factors.
In both forward and backward stepwise multivariable Cox
regression analyses, HDL-C (together with smoking and
hypertension) was retained as a signiﬁcant predictor of both
MCVE and all-cause mortality in men. The corresponding
stepwise analyses in women expelled HDL-C from the
models for both MCVE and all-cause mortality. Smoking,
diabetes, and previous myocardial infarction were retained
as independent predictors of MCVE in the stepwise mod-
els in women, whereas smoking and previous myocardial
infarction were retained as independent predictors of all-
cause mortality. Including sex and the interaction between
sex and HDL-C and adjusting for potentially confounding
riskfactorsinamultivariableCoxregressionanalysisshowed
a borderline signiﬁcant sex diﬀerence in the strength of the
association between HDL-C and time to MCVE (P = .051)
and to all-cause mortality (P = .067).
When excluding individuals with prevalent stroke or
myocardial infarction at baseline, the association of adjusted
HDL-C to MCVE was unchanged in both men and women,
whereas the association to all-cause mortality was slightly
strengthened. In men the resulting hazard ratio of adjusted
HDL-C to all-cause mortality was 0.68 (95% CI 0.54–0.87,
P = .002) and in women .88 (95% CI 0.72–1.06, P = .18).
Excluding the 15 individuals on lipid lowering therapy did
not result in any substantial changes in the results of the Cox
regression analyses.
The National Cholesterol Education Program Adult
Treatment Panel III (NCEP-ATP III) has recommended
HDL-C levels of <40mg/dL for men and <50mg/dL for
women as one of the components to deﬁne the metabolic
syndrome [13]. Some characteristics of the 75-year-old
men with HDL-C levels <40mg/dL or ≥40mg/dL are
shown in Table 3. Men with low HDL-C had signiﬁcantly
higher prevalence of diabetes and hypertension as well as
signiﬁcantly higher levels of serum triglycerides than those
with high HDL-C. The diﬀerence in plasma glucose was
nearly signiﬁcant.
Figure 1showsKaplan-Meiercurvesforall-causemortal-
ity of men and women with low and high HDL-C according
to the NCEP-ATP III recommended cutoﬀ levels. Twenty-
four men and 46 women were thereby classiﬁed by these
limits as having low HDL-C. The diﬀerence in survival
between the low and high HDL-C levels was signiﬁcant for
men(log-rankstatistics =8.92,P = .003) butnot forwomen
(log-rank statistics = 2.86, P = .091).
4. Discussion
4.1. HDL-C. The present investigation comprises 70% of
all 75-year-old people in a deﬁned geographical area and
reasonably reﬂects a general population of this age. The
main ﬁnding was that low serum levels of HDL-C were con-
siderably stronger associated with increased cardiovascular
morbidityandmortalityinmenthaninwomenduringlong-
term follow-up in a population-based cohort of 75 year-old
people.Onthecontrary,thelevelsoftotalcholesterol,LDL-C
and non-HDL-C had no signiﬁcant impact on the long-term
prognosis in either sex.
It is well known that a low serum level of HDL-C is a
powerful predictor of increased cardiovascular risk in young
and middle-aged people [3, 5, 14–16]. Interestingly, this
association was observed even among patients with LDL-C
concentration below 70mg/dL during statin treatment [6].
SimilarﬁndingsasoursconcerningHDL-C,survival,and
sex have been reported from a 13-year follow-up study of4 Current Gerontology and Geriatrics Research
Table 2:Hazardratiosformajorcardiovasculareventdeﬁnedashospitalizationordeathcausedbymyocardialinfarction,stroke,orruptured
aortic aneurysm or all-cause mortality according to serum levels of cholesterol and its subfractions.
Major cardiovascular event All-cause mortality
Men (n = 195) Women (n = 199) Men (n = 210) Women (n = 222)
HR (95% CI)∗ P HR (95% CI)∗ P HR (95% CI)∗ P HR (95% CI)∗ P
Total cholesterol 1.01 (0.96–1.07) .68 1.00 (0.93–1.07) .94 0.97 (0.92–1.02) .29 0.95 (0.90–1.00) .065
LDL-C 1.02 (0.96–1.09) .44 1.02 (0.93–1.11) .72 0.97 (0.92–1.03) .34 0.99 (0.92–1.06) .73
Non-HDL-C 1.03 (0.98–1.09) .25 1.01 (0.95–1.08) .77 0.99 (0.95–1.04) .82 0.97 (0.93–1.02) .20
Total cholesterol/HDL-C ratio 1.19 (1.00–1.40) .046 1.13 (0.89–1.45) .32 1.10 (0.95–1.29) .20 1.07 (0.90–1.29) .44
HDL-C 0.76 (0.61–0.94) .011 0.93 (0.78–1.10) .40 0.78 (0.65–0.94) .009 0.93 (0.82–1.07) .32
HDL-C adjusted† 0.71 (0.55–0.90) .006 1.01 (0.83–1.23) .94 0.76 (0.62–0.94) .011 0.93 (0.80–1.07) .31
∗Hazard ratios and 95% conﬁdence intervals for every unit increase of the total cholesterol/HDL-C ratio and for every 10mg/dL increase of the other
independent variables.
†Adjusted for smoking, non-HDL-C, triglycerides, diabetes, hypertension, previous stroke, and previous myocardial infarction.
Table 3: Characteristics of the 75-year-old men with high or low HDL-C. Cutoﬀ level of HDL-C (40mg/dL) according to recommendation
from the National Cholesterol Education Program—Adult Treatment Panel III. Values are median (interquartile range) and number (%).
HDL-C <40mg/dL HDL-C ≥40mg/dL P-value
(n = 24) (n = 186)
Total cholesterol, mg/dL 217 (207–246) 232 (205–259) .33
LDL-C, mg/dL∗ 147 (127–166) 148 (119–173) .62
HDL-C, mg/dL 36 (34–38) 55 (49–62)
Non-HDL-C, mg/dL 179 (172–207) 175 (151–205) .16
Total cholesterol/HDL-C ratio 6.2 (5.6–6.5) 4.2 (3.5–4.9) <.001
Triglycerides, mg/dL 214 (142–271) 125 (96–161) <.001
Body mass index, kg/m2 25.4 (23.6–27.4) 25.2 (23.6–26.9) .32
Systolic blood pressure, mmHg∗ 170 (142–180) 160 (150–180) .76
Diastolic blood pressure, mmHg∗ 90 (80–90) 85 (80–90) .50
Current smoking 4 (17) 30 (16) 1.00
Previous myocardial infarction 4 (17) 27 (14) .76
Previously known hypertension 11 (48) 44 (24) .022
Diabetes 5 (21) 10 (5) .018
Lipid lowering drugs 0 (0) 8 (4)
∗Data on blood pressure and LDL-C were missing in 11 and 8 cases, respectively.
a Finnish population, 65–74 years old, covering 35% of all
residents in a deﬁned geographical area (participation rate
71%)[17]andtheBronxagingstudyconcerning75–85-year-
o l dm e na n dw o m e n[ 9]. However, a recent meta-analysis
found no sex disparity in the negative association between
HDL-C and cardiovascular outcome in the elderly [4].
Among elderly men, our ﬁndings concerning HDL-C are
consistent with results from the Whitehall population, mean
age 77 [7], and a Swedish study of 785 men, aged 77 [10].
LowerlevelsofHDL-Chavebeenfoundtobeadiscriminator
of cardiac events among 60-year-old women in the Nurses’
Health Study [18].
The median HDL-C level was 16% lower in men than
in women, and it might be hypothesized that this diﬀerence
is related to the sex disparity in prognostic impact of HDL-
C demonstrated by us. However, in middle-aged people,
the inverse relationship between HDL-C and coronary heart
disease extends over a broad range of HDL-C levels [14],
including the range found in our elderly cohort. The clinical
laboratory report of HDL-C refers to the mass of cholesterol
within the HDL-C particles. Given the extraordinary biolog-
ical diversity of HDL particles, these measurements do not
provide much functional information [19]. Therefore, it is
diﬃcult to ﬁnd a biological explanation for the sex disparity
in prognostic importance of HDL-C.
4.2. Total Cholesterol and LDL-C. Declining total cholesterol
levels have been found in people above 65 in the Car-
diovascular Health Study [20]. The decline was found to
be associated with male gender, advanced age, weight loss,
and higher white blood cell count. Weverling-Rijnsburger
[21] has reported declining levels of total cholesterol in
individuals above 85 years of age.
Thereisstrongevidenceofapositiveassociationbetween
cholesterol levels and cardiovascular disease as well as
cardiovascular death in young and middle-aged people [1–
3, 22–25]. Cardiovascular disease is the leading cause ofCurrent Gerontology and Geriatrics Research 5
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Figure 1: Kaplan-Meier curve illustrating all-cause mortality
accordingtocutoﬀlevelsofHDLCasrecommendedbytheNational
Cholesterol Education Program—Adult Treatment Panel III (men:
low HDL <40mgdL, high HDL = 40mgdL; women: low HDL
<50mgdL, high HDL = 50mgdL). Men (women) at risk at 2,4,6,
and 8 years was 197 (218), 172 (213), 152 (198), and 138 (185).
death among the elderly but the importance of hyperc-
holesterolemia as a risk factor in persons above 70 remains
controversial. Most studies have noted that the risk weakens
with advancing age [4, 26]. Some prospective observational
studies have reported positive associations between total
cholesterol levels and both cardiovascular disease as well
as all-cause mortality among the elderly [27, 28], whereas
other studies have reported no such associations [7, 29, 30].
In people above 85 years, high cholesterol has even been
reported to be associated with increased survival [21].
4.3. Clinical Implications. In the present investigation there
was no increase in mortality above recommended limits for
high total cholesterol, LDL-C [13, 25], and the quotient
total cholesterol/HDL-C [31]. This calls into question the
valueofcholesterolloweringin75-year-oldpeople.However,
present studies suggest that, at least in secondary prevention,
the beneﬁt of lowering cholesterol is independent of age,
though detailed information concerning people in their
eighties and nineties is lacking. In the 4S study [32] there
was no diﬀerence in treatment beneﬁt in patients aged
below and above 60 years. Similarly, the pooled analysis
of the Pravastatin Atherosclerosis Intervention Program,
PROSPER, suggested that risk reduction, if any, was greater
in patients older than 65 years [33], which is also conﬁrmed
in large-meta analyses of major clinical studies [34, 35].
However an upper age limit for the beneﬁt of lipid-lowering
drugs may be suspected in view of the positive association
between high cholesterol and longevity in people above 85
years of age [21]. Empirical data on the possible value of
cholesterol lowering drugs above 85 years of age are lacking.
Established atherosclerotic disease is common in people
above75,andasymptomaticindividualsinthisagegroupare
at high risk of developing symptomatic atherosclerotic dis-
ease. Consequently, the absolute risk of known or unknown
atherosclerotic diseases as well as death from such diseases
is considerable. When used for secondary prevention, statin
therapy has been reported to be strongly protective of
morbidity and mortality in atherosclerotic cardiovascular
disease also in people aged more than 75 years [35, 36].
In primary prevention, the AFCAPS/TexCAPS study, which
recruited participants aged 43–73 years, showed beneﬁt from
cholesterol lowering drugs in both men and women also
in the older participants [37]. The beneﬁt of common
cholesterol lowering drugs in the elderly despite weakening
of cholesterol as a risk factor rises suspicion of beneﬁts from
such drugs mediated by non-LDL-C lowering mechanisms.
4.4. Strengths and Limitations. The restriction of our inves-
tigation to one age class enables us to leave age out of
account as a confounding factor, creating the possibility of
a meaningful estimation of the relations between survival
and serum levels of cholesterol and its subfractions, despite
the relatively small number participants of the study. Fur-
thermore,becauseofhighparticipationrate,theparticipants
are more representative for the population in a deﬁned
geographical area than described in most other studies on
this topic. These advantages are, however, obtained at the
cost of the diﬃculties to generalize our ﬁndings to people
not being 75 years old and to people from other geographical
areas. However, it seems likely that our results are applicable
to North European and white North American people in
their seventies.
In conclusion, low serum levels of HDL-C were signif-
icantly associated with increased cardiovascular morbidity
and mortality in men but not in women during long-term
follow-up in this population-based cohort of 75-year-old
people. ElderlymenwithHDL-C <40mg/dLshouldbegiven
attention for cardiovascular prevention. The serum levels of
total cholesterol, LDL-C, and non-HDL-C had no signiﬁcant
impact on prognosis. This calls into question the value of
cholesterol lowering in 75-year-old people.
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